Edwards Lifesciences Corp. (NYSE:EW) received a $140.00 target price from equities researchers at Canaccord Genuity in a note issued to investors on Tuesday. The firm presently has a “buy” rating on the medical research company’s stock. Canaccord Genuity’s price target indicates a potential upside of 61.18% from the stock’s previous close.

Several other equities research analysts also recently weighed in on EW. Morgan Stanley raised their target price on shares of Edwards Lifesciences Corp. from $110.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, July 27th. Bank of America Corp. upgraded shares of Edwards Lifesciences Corp. from a “neutral” rating to a “buy” rating and set a $130.00 target price for the company in a research note on Wednesday, July 27th. BTIG Research raised their target price on shares of Edwards Lifesciences Corp. from $122.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, July 27th. Leerink Swann raised their target price on shares of Edwards Lifesciences Corp. from $125.00 to $130.00 and gave the company an “outperform” rating in a research note on Wednesday, July 27th. Finally, Jefferies Group restated a “buy” rating and issued a $125.00 target price on shares of Edwards Lifesciences Corp. in a research note on Wednesday, July 27th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-two have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $117.68.

Analyst Recommendations for Edwards Lifesciences Corp. (NYSE:EW)

Shares of Edwards Lifesciences Corp. (NYSE:EW) opened at 86.86 on Tuesday. Edwards Lifesciences Corp. has a 1-year low of $72.20 and a 1-year high of $121.75. The stock has a 50 day moving average price of $102.00 and a 200 day moving average price of $106.84. The stock has a market capitalization of $18.57 billion, a price-to-earnings ratio of 34.33 and a beta of 0.71.

Edwards Lifesciences Corp. (NYSE:EW) last announced its earnings results on Tuesday, October 25th. The medical research company reported $0.68 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.68. The company earned $739.40 million during the quarter, compared to the consensus estimate of $749.14 million. Edwards Lifesciences Corp. had a net margin of 19.24% and a return on equity of 24.32%. Edwards Lifesciences Corp.’s revenue was up 20.1% compared to the same quarter last year. During the same period last year, the firm earned $0.54 earnings per share. Equities research analysts anticipate that Edwards Lifesciences Corp. will post $2.88 EPS for the current year.

In other Edwards Lifesciences Corp. news, VP Huimin Wang sold 13,650 shares of the business’s stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $120.04, for a total value of $1,638,546.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 49,100 shares of the business’s stock in a transaction dated Thursday, October 27th. The shares were sold at an average price of $92.77, for a total transaction of $4,555,007.00. The disclosure for this sale can be found here. 2.37% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of EW. Silvercrest Asset Management Group LLC bought a new stake in Edwards Lifesciences Corp. during the first quarter worth about $204,000. Schonfeld Strategic Advisors LLC bought a new stake in Edwards Lifesciences Corp. during the first quarter worth about $242,000. LPL Financial LLC increased its stake in Edwards Lifesciences Corp. by 1.0% in the first quarter. LPL Financial LLC now owns 43,296 shares of the medical research company’s stock worth $4,472,000 after buying an additional 438 shares during the period. Arizona State Retirement System increased its stake in Edwards Lifesciences Corp. by 2.0% in the first quarter. Arizona State Retirement System now owns 61,800 shares of the medical research company’s stock worth $5,451,000 after buying an additional 1,200 shares during the period. Finally, Seven Eight Capital LLC increased its stake in Edwards Lifesciences Corp. by 109.1% in the first quarter. Seven Eight Capital LLC now owns 9,200 shares of the medical research company’s stock worth $812,000 after buying an additional 4,800 shares during the period. Institutional investors own 83.99% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Edwards Lifesciences Corp. (EW) Given a $140.00 Price Target by Canaccord Genuity Analysts” was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2016/11/24/edwards-lifesciences-corp-ew-given-a-140-00-price-target-by-canaccord-genuity-analysts.html.

About Edwards Lifesciences Corp.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

5 Day Chart for NYSE:EW

Receive News & Stock Ratings for Edwards Lifesciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp. and related stocks with our FREE daily email newsletter.